Validation of the ALFA-1200 model in older patients with AML treated with intensive chemotherapy-Reference-Cited by-同舟云学术

Validation of the ALFA-1200 model in older patients with AML treated with intensive chemotherapy

Published:2023-03-03 Issue:5 Volume:7 Page:828-831
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Abbas Hussein A.¹²^ORCID,Sun Hanxiao¹³^ORCID,Pierce Sherry¹,Kanagal-Shamanna Rashmi⁴^ORCID,Li Ziyi⁵,Yilmaz Musa¹^ORCID,Borthakur Gautam¹,DiPippo Adam J.⁶,Jabbour Elias¹,Konopleva Marina¹^ORCID,Short Nicholas J.¹,DiNardo Courtney¹^ORCID,Daver Naval¹^ORCID,Ravandi Farhad¹,Kadia Tapan M.¹

Affiliation:

1. 1Department of Leukemia, MD Anderson Cancer Center, Houston, TX

2. 2Department of Genomic Medicine, MD Anderson Cancer Center, Houston, TX

3. 3School of Public Health, University of Texas, Houston, TX

4. 4Department of Hematopathology, MD Anderson Cancer Center, Houston, TX

5. 5Department of Biostatistics, MD Anderson Cancer Center, Houston, TX

6. 6Department of Pharmacy Clinical Programs, MD Anderson Cancer Center, Houston, TX

Publisher

American Society of Hematology

Subject

Hematology

Link

https://ashpublications.org/bloodadvances/article-pdf/7/5/828/2039057/blooda_adv-2022-007172-main.pdf

Reference10 articles.

1. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel;Döhner;Blood,2017

2. Precision oncology for acute myeloid leukemia using a knowledge bank approach;Gerstung;Nat Genet,2017

3. Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy;Itzykson;Blood,2021

4. Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia;Metzeler;Blood,2016

5. Integrated transcriptomic and genomic analysis improves prediction of complete remission and survival in elderly patients with acute myeloid leukemia;Österroos;Blood Cancer J,2020

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial;Blood;2023-11-16